A phase I study of methotrexate administration following 5-fluorouracil

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 5, 1996, Pages 492-499

  White, Robert M ^a,b  

^a HOWARD UNIVERSITY CANCER CENTER   (United States)

^b Center for Drug Evaluation and Research   (United States)

Author keywords

Antifolate; Drug antagonism; Fluoropyrimidine; Head and neck cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; METHOTREXATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGUS CANCER; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; RECTUM CANCER; SOLID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SURVIVAL RATE;

EID: 0029810735     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199610000-00013     Document Type: Article

References (41)

1. Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 1981;256:1695-704.
2. Fernandes DJ, Moroson BA, Bertino JR. The role of methotrexate and dihydrofolate polyglutamates in the enhancement of fluorouracil action by methotrexate. Cancer Treat Rep 1981;65(Suppl 1):29-35.
3. Benz C, Cadman E. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. Cancer Res 1981;41:994-9.
4. Donehower RC, Allegra JC, Lippman ME, Chabner BA. Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum free culture. Eur J Cancer 1980;16: 655-61.
5. Browman GP, Archibald SD, Young JEM, et al. Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. J Clin Oncol 1983;1:787- 92.
6. Coates AS, Tattersall MHN, Swanson C, Hedley D, Fox RM, Raghavan D. Combination therapy with methotrexate and 5- fluorouracil: a prospective randomized clinical trial of order of administration. J Clin Oncol 1984;2:756-61.
7. Browman GP, Levine MN, Goodyear MD, et al. Methotrexate/ fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial. J Clin Oncol 1988;6: 963-8.
8. Mulder JH, Smink T, Van Putten LM. 5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling. Eur J Cancer Clin Oncol 1981;17:831-7.
9. Robbins TJ, Bowen D, Bui QQ, Tran M-T. Modulation of high- dose methotrexate toxicity by a non-toxic level of 5-fluorouracil. Toxicology 1986;41:61-73.
10. 14C]formate incorporation into RNA and protein. Eur J Cancer 1980;16:893-9.
11. Robbins TJ, Bowen D. Toxicity, pathological effects, and antineoplastic activity of a non-toxic dose of 5-fluorouracil in combination with methotrexate. Anticancer Res 1988;8:43-50.
12. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
13. Jolivet J, Faucher F, Pinard M-F. Influence of intracellular folates on methotrexate metabolism and cytotoxicity. Biochem Pharmacol 1987;36:3310-2.
14. Browman GP, Goodyear MDE, Levine MN, Russell R, Archibald SD, Young JEM. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol 1990;8:203-8.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
16. Herbert V. Making sense of laboratory tests of folate status: folate requirements to sustain normality. Am J Hematol 1987;26:199- 207.
17. White RM, Myers EM, Ashayeri E, Gumbs RV, Pressior R. Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics. Am J Clin Oncol (CCT) 1992;15:45-55.
18. Kamen BA, Nylen PA, Camitta BM, Bertino JR. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981;49: 355-60.
19. Sirotnak FM, Donsbach RC, Dorick DM, Moccio DM. High- dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models. Cancer Treat Rep 1977;61:565-74.
20. Hansen HH, Selawry OS, Holland JF, McCall CB. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971;25:298-305.
21. Bertino JR. Clinical use of methotrexate - with emphasis on use of high doses. Cancer Treat Rep 1981;65(Suppl. 1):131-5.
22. Levin M, Mosher MB, DeConti RC, et al. Improved therapeutic index of methotrexate with "leucovorin rescue." Cancer Res 1973;33:1729-34.
23. Yap B-S, McCredie KB, Keating MJ, Bodey GP, Freireich EJ. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 1981;65(Suppl. 1):83-7.
24. Schornagel JH, Leyva A, Pinedo HM. Methotrexate with thymidine protection or rescue in advanced head and neck cancer: a Phase II study. Cancer Treat Rep 1984;68:543-5.
25. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5:2017-31.
26. Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer 1980;63:995-1007.
27. Mihranian MH, Wang YM, Daly JM. Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer 1984;54:2268-71.
28. Rentschler RE, Wilbur DW, Petti GH, et al. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinoma - a prospective, randomized study. J Clin Oncol 1987;5:278-85.
29. Swenseid ME, Bethell FH, Bird OD. The concentration of folic acid in leukocytes observations on normal subjects and persons with leukemia. Cancer Res 1951;11:864-7.
30. Taylor SG, McGuire WP, Hauck WW, Showel JL, Lad TE. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 1984;2:1006-11.
31. Ohnuma T, Arkin H, Minowada J, Holland JF. Differential chemotherapeutic susceptibility of human T-lymphocytes and B-lymphocytes in culture. J Natl Cancer Inst 1978;60:749-52.
32. Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990;299:153-7.
33. Wright JE, Dreyfuss A, El-Magharbel I, et al. Selective expansion of 5-10-methylenetetrahydrofolate pools and modulation of 5- fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 1989;49:2592-6.
34. Allegra CJ, Chabner BA, Sholar PW, Bagley C, Drake JC, Lippman ME. Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin. NCI Monogr 1987;5:199-202.
35. Spears CP, Frosing R, Gustavsson BG. Intracellular pharmacodynamics of 5-fluorouracil in tumors and normal tissues. Proc ASCO 1986;5:37.
36. Cohen JL, Irwin LE, Marshall GJ, Darvey H, Bateman JJ. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC- 19893). Cancer Chemother Rep 1974;58:723-31.
37. Spears CP, Gustavsson BG, Mitchell MS, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984;44: 4144-50.
38. Moran RG. Leucovorin enhancement of the effects of the fluo- ropyrimidines on thymidylate synthase. Cancer 1989;63:1008- 12.
39. Myers CE, Young RC, Chabner BA. The biochemical determinants of 5-fluorouracil response in vivo: the role of deoxyuridylate pool expansion. J Clin Invest 1975;56:1231-8.
40. Yin M-B, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983;23:190-7.
41. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984;25:303-9.